What Is a Success Rate of KRYSTEXXA for Gout Treatment?
KRYSTEXXA has demonstrated a strong success rate for treating chronic refractory gout, particularly in patients who have not responded to traditional gout medications. Clinical studies have shown that approximately 42% of patients treated with KRYSTEXXA achieve normal uric acid levels, which can lead to a reduction in gout flares, the dissolution of tophi, and improved joint function. While not all patients will experience the same level of success, those who respond well to KRYSTEXXA often see a significant improvement in their symptoms within the first six months of treatment.
KRYSTEXXA is particularly effective in reducing tophi, the large deposits of uric acid crystals that can cause severe pain and joint damage. In patients with advanced gout, KRYSTEXXA has been shown to shrink or eliminate tophi over time, which can help restore mobility and improve quality of life. While the success rate varies from patient to patient, KRYSTEXXA offers hope for individuals with chronic gout who have not found relief through other treatments.
